Atara Biotherapeutics
ATRA
122 hedge funds and large institutions have $1.13B invested in Atara Biotherapeutics in 2020 Q2 according to their latest regulatory filings, with 32 funds opening new positions, 61 increasing their positions, 19 reducing their positions, and 21 closing their positions.
221% more repeat investments, than reductions
Existing positions increased: 61 | Existing positions reduced: 19
200% more funds holding in top 10
Funds holding in top 10: 1 → 3 (+2)
144% more capital inflows, than outflows
Capital inflows: $267M | Capital outflows: $109M
101% more call options, than puts
Call options by funds: $1.5M | Put options by funds: $746K
52% more first-time investments, than exits
New positions opened: 32 | Existing positions closed: 21
10% more funds holding
Funds holding: 111 → 122 (+11)
1.05% more ownership
Funds ownership: 107.32% → 108.38% (+1.1%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CCM
Consonance Capital Management
New York
|
+$52.9M |
| 2 |
Goldman Sachs
New York
|
+$29.2M |
| 3 |
Baupost Group
Boston,
Massachusetts
|
+$16.3M |
| 4 |
Maverick Capital
Dallas,
Texas
|
+$15.7M |
| 5 |
RG
Redmile Group
San Francisco,
California
|
+$15.7M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Federated Hermes
Pittsburgh,
Pennsylvania
|
-$27.9M |
| 2 |
Morgan Stanley
New York
|
-$27.1M |
| 3 |
Eagle Asset Management
St Petersburg,
Florida
|
-$14.4M |
| 4 |
Farallon Capital Management
San Francisco,
California
|
-$12.8M |
| 5 |
Carillon Tower Advisers
St. Petersburg,
Florida
|
-$9.49M |
ATRA Hedge Fund Activity: Q2 2020 in Review
122 of the 4,890 institutional investors tracked by Wall St. Rank reported a position in Atara Biotherapeutics (ATRA) for Q2 2020, worth a combined $1.13B — up 111% from $535M a quarter earlier.
Buyers outnumbered sellers: 32 funds opened new ATRA positions and 21 closed out — a net gain of 11 holders — while 61 added to existing stakes and 19 trimmed.
The largest buyer was Consonance Capital Management, opening a new position worth an estimated $52.9M. The largest seller was Federated Hermes, cutting an estimated $27.9M.
- 122 institutional investors held Atara Biotherapeutics (ATRA) as of Q2 2020, up from 111 in Q1 2020.
- Funds reported $1.13B of Atara Biotherapeutics stock for Q2 2020, up 111% quarter-over-quarter.
- 32 funds opened new Atara Biotherapeutics positions in Q2 2020 and 21 closed out, a net change of +11 holders.
- The largest Atara Biotherapeutics buyer in Q2 2020 was Consonance Capital Management, an estimated $52.9M added.
- The largest Atara Biotherapeutics seller in Q2 2020 was Federated Hermes, an estimated $27.9M sold.
Based on aggregated 13F filings for Q2 2020.